妊娠高血圧腎症診断の世界市場 - 市場考察、競合情勢、市場予測（2032年）

世界の妊娠高血圧腎症診断の市場規模は、2025年～2032年の予測期間にCAGRで3.67%の成長が見込まれます。市場の成長は、主に妊娠高血圧腎症の罹患率の増加とそれに関連する危険因子、妊婦や医療従事者の意識の高まりによって促進されます。さらに、主要市場企業による継続的な製品開発活動が、2025年～2032年の予測期間に市場の拡大にさらに寄与すると予測されます。

妊娠高血圧腎症診断の市場力学

世界中での妊娠高血圧腎症の有病率の上昇が、妊娠高血圧腎症診断市場全体を大きく押し上げています。世界保健機関（WHO）（2024）のデータによると、妊娠高血圧腎症は世界全体の妊娠の2～8%に影響を及ぼします。この妊娠に関連した合併症は、主に妊娠20週目以降に起こる高血圧と臓器障害の徴候が特徴で、多くの女性が直面するため、早期の正確な検出方法へのニーズは着実に高まっています。

さらに、UK Obstetric Surveillance System（UKOSS）の研究では、重度の肥満患者では妊娠高血圧腎症の罹患率が9%であったのに対し、肥満でない対照群では2%でした。また、Preeclampsia Foundation Organization（2024）が提供したデータによると、妊娠高血圧症、慢性高血圧症、妊娠高血圧腎症、子癇などの疾患を含む妊娠高血圧症候群（HDP）は、全世界の全妊娠の約5～10%に影響を及ぼしています。

妊娠高血圧腎症はHDPの主要かつもっとも重篤な病態であり、多くの場合、血圧上昇と臓器系、特に肝臓と腎臓への障害の徴候を特徴とします。HDPが重大な健康リスクをもたらし続けることから、先進の妊娠高血圧腎症診断技術の採用が世界中で増加すると予測されます。母体年齢の上昇、肥満、糖尿病、高血圧、多胎妊娠などの要因が、妊娠高血圧腎症の発症リスク増大の主因となっています。そのため、世界中で妊娠高血圧腎症の患者が増加しており、妊娠高血圧腎症診断市場の成長を後押しすると予測されます。

妊婦の意識の高まりも、妊娠高血圧腎症診断市場の主な成長促進要因です。例えば2025年1月、1月23日のMaternal Health Awareness Dayを記念して、Preeclampsia FoundationはPatients & Purposeと共同でGAP-SPIRINキャンペーンを開始しました。このエビデンスに基づく教育活動は、妊娠高血圧腎症の予防と妊産婦の健康格差に対処するための低用量アスピリンの使用を促進するものです。

このキャンペーンは、黒人の妊産婦が直面する特有の課題に関する情報と低用量アスピリン予防に関するガイダンスを組み合わせ、医療提供者が妊娠高血圧腎症のリスクをより適切に管理できるようにするものです。妊娠高血圧腎症は、妊娠中と産褥期に生命を脅かす危険性のある重篤な高血圧性疾患です。これは妊産婦の健康危機における中心的な問題であり、黒人の母親に偏って影響を及ぼし、60%の確率で発症します。

市場の主要企業による革新的な診断検査の開発は、市場成長に大きく寄与しています。Mirvieは2022年5月、同社のMirvie Preeclampsia Testが米国FDAのBreakthrough Device指定を受けたと発表しました。この画期的な検査は、症状が出る前に女性の妊娠高血圧腎症発症リスクを個別に評価するように設計されています。この検査は、独自のMirvie RNAプラットフォームによって行われ、各妊娠に固有の生物学的シグナルを分析し、予期せぬ合併症のリスクを予測することで、より早く、より個別化された臨床介入を可能にします。

こうした有望な成長要因にもかかわらず、妊娠高血圧腎症診断市場は課題に直面しています。患者や医療提供者の認識が限定的であることや、妊娠高血圧腎症診断検査の精度における限界は、予測期間の市場成長を妨げる可能性のある重大な抑制要因です。

当レポートでは、世界の妊娠高血圧腎症診断市場について調査分析し、市場規模と予測、過去3年の製品/技術開発、市場の主要企業、利用可能な機会などの情報を提供しています。

目次

第1章 妊娠高血圧腎症診断市場レポートのイントロダクション

第2章 妊娠高血圧腎症診断市場のエグゼクティブサマリー

• 市場の概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 妊娠高血圧腎症診断市場の主な要因の分析

• 妊娠高血圧腎症診断市場の促進要因
• 妊娠高血圧腎症診断市場の抑制要因と課題
• 妊娠高血圧腎症診断市場の機会

第6章 妊娠高血圧腎症診断市場におけるポーターのファイブフォース分析

第7章 妊娠高血圧腎症診断市場の評価

• 検体タイプ別
  • 血液検査
  • 尿検査
• 製品タイプ別
  • 試薬・キット
  • 器具
• 検査方式
  • 実験室ベースの検査
  • ポイントオブケア検査（POCT）
• エンドユーザー別
  • 病院
  • 専門クリニック
  • 診断センター
  • その他
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 妊娠高血圧腎症診断市場の企業と製品のプロファイル

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Labcorp
• PerkinElmer
• ARUP Laboratories
• Siemens Healthineers AG
• QuidelOrtho Corporation
• Revvity
• Randox Laboratories
• CERCA Biotech

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Preeclampsia Diagnostics Market in Global (2022-2032)
• Table 3: Preeclampsia Diagnostics Market in Global by Sample Type (2022-2032)
• Table 4: Preeclampsia Diagnostics Market in Global by Product Type (2022-2032)
• Table 5: Preeclampsia Diagnostics Market in Global by Mode of Testing (2022-2032)
• Table 6: Preeclampsia Diagnostics Market in Global by End-User (2022-2032)
• Table 7: Preeclampsia Diagnostics Market in Global by Geography (2022-2032)
• Table 8: Preeclampsia Diagnostics Market in North America (2022-2032)
• Table 9: Preeclampsia Diagnostics Market in the United States (2022-2032)
• Table 10: Preeclampsia Diagnostics Market in Canada (2022-2032)
• Table 11: Preeclampsia Diagnostics Market in Mexico (2022-2032)
• Table 12: Preeclampsia Diagnostics Market in Europe (2022-2032)
• Table 13: Preeclampsia Diagnostics Market in France (2022-2032)
• Table 14: Preeclampsia Diagnostics Market in Germany (2022-2032)
• Table 15: Preeclampsia Diagnostics Market in United Kingdom (2022-2032)
• Table 16: Preeclampsia Diagnostics Market in Italy (2022-2032)
• Table 17: Preeclampsia Diagnostics Market in Spain (2022-2032)
• Table 18: Preeclampsia Diagnostics Market in the Rest of Europe (2022-2032)
• Table 19: Preeclampsia Diagnostics Market in Asia-Pacific (2022-2032)
• Table 20: Preeclampsia Diagnostics Market in China (2022-2032)
• Table 21: Preeclampsia Diagnostics Market in Japan (2022-2032)
• Table 22: Preeclampsia Diagnostics Market in India (2022-2032)
• Table 23: Preeclampsia Diagnostics Market in Australia (2022-2032)
• Table 24: Preeclampsia Diagnostics Market in South Korea (2022-2032)
• Table 25: Preeclampsia Diagnostics Market in Rest of Asia-Pacific (2022-2032)
• Table 26: Preeclampsia Diagnostics Market in the Rest of the World (2022-2032)
• Table 27: Preeclampsia Diagnostics Market in the Middle East (2022-2032)
• Table 28: Preeclampsia Diagnostics Market in Africa (2022-2032)
• Table 29: Preeclampsia Diagnostics Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Preeclampsia Diagnostics Market in Global (2022-2032)
• Figure 3: Preeclampsia Diagnostics Market in Global by Sample Type (2022-2032)
• Figure 4: Preeclampsia Diagnostics Market in Global by Product Type (2022-2032)
• Figure 5: Preeclampsia Diagnostics Market in Global by Mode of Testing (2022-2032)
• Figure 6: Preeclampsia Diagnostics Market in Global by End-User (2022-2032)
• Figure 7: Preeclampsia Diagnostics Market in Global by Geography (2022-2032)
• Figure 8: Preeclampsia Diagnostics Market in North America (2022-2032)
• Figure 9: Preeclampsia Diagnostics Market in the United States (2022-2032)
• Figure 10: Preeclampsia Diagnostics Market in Canada (2022-2032)
• Figure 11: Preeclampsia Diagnostics Market in Mexico (2022-2032)
• Figure 12: Preeclampsia Diagnostics Market in Europe (2022-2032)
• Figure 13: Preeclampsia Diagnostics Market in France (2022-2032)
• Figure 14: Preeclampsia Diagnostics Market in Germany (2022-2032)
• Figure 15: Preeclampsia Diagnostics Market in United Kingdom (2022-2032)
• Figure 16: Preeclampsia Diagnostics Market in Italy (2022-2032)
• Figure 17: Preeclampsia Diagnostics Market in Spain (2022-2032)
• Figure 18: Preeclampsia Diagnostics Market in the Rest of Europe (2022-2032)
• Figure 19: Preeclampsia Diagnostics Market in Asia-Pacific (2022-2032)
• Figure 20: Preeclampsia Diagnostics Market in China (2022-2032)
• Figure 21: Preeclampsia Diagnostics Market in Japan (2022-2032)
• Figure 22: Preeclampsia Diagnostics Market in India (2022-2032)
• Figure 23: Preeclampsia Diagnostics Market in Australia (2022-2032)
• Figure 24: Preeclampsia Diagnostics Market in South Korea (2022-2032)
• Figure 25: Preeclampsia Diagnostics Market in Rest of Asia-Pacific (2022-2032)
• Figure 26: Preeclampsia Diagnostics Market in the Rest of the World (2022-2032)
• Figure 27: Preeclampsia Diagnostics Market in the Middle East (2022-2032)
• Figure 28: Preeclampsia Diagnostics Market in Africa (2022-2032)
• Figure 29: Preeclampsia Diagnostics Market in South America (2022-2032)
• Figure 30: Market Drivers
• Figure 31: Market Barriers
• Figure 32: Marker Opportunities
• Figure 33: PORTER'S Five Force Analysis

Preeclampsia Diagnostics Market by Sample Type (Blood Test and Urine Test), Product Type (Reagents & Kits and Instruments), Mode of Testing (Laboratory-based Testing and Point-of-care Testing (POCT)), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of preeclampsia worldwide & associated risk factors and growing awareness among pregnant women and healthcare professionals

The preeclampsia diagnostics market is estimated to grow at a CAGR of 3.67% during the forecast period from 2025 to 2032. The growth of the preeclampsia diagnostics market is primarily driven by the increasing incidence of preeclampsia and its associated risk factors, along with rising awareness among pregnant women and healthcare professionals. Additionally, ongoing product development initiatives by key market players are expected to further contribute to the market's expansion during the forecast period from 2025 to 2032.

Preeclampsia Diagnostics Market Dynamics:

The rising prevalence of preeclampsia globally is significantly boosting the overall market for preeclampsia diagnostics. According to the data provided by the World Health Organization (2024), preeclampsia affects 2-8% of pregnancies worldwide. As more women face this pregnancy-related complication, primarily marked by high blood pressure and signs of organ damage usually occurring after the 20th week of gestation, the need for early and accurate detection methods is steadily increasing.

Additionally, the UK Obstetric Surveillance System (UKOSS) study showed an incidence of preeclampsia of 9% in severely obese patients compared to 2% of nonobese controls. Also, according to the data provided by the Preeclampsia Foundation Organization (2024), hypertensive disorders of pregnancy (HDPs), which include conditions such as gestational hypertension, chronic hypertension, preeclampsia, and eclampsia, affected approximately 5-10% of all pregnancies worldwide.

Preeclampsia is a major and most severe form of HDP, often characterized by elevated blood pressure and signs of damage to organ systems, particularly the liver and kidneys. As HDPs continue to pose significant health risks, the adoption of advanced preeclampsia diagnostic technologies is expected to boost across the globe. Factors such as increasing maternal age, obesity, diabetes, hypertension, and multiple pregnancies are key contributors to the growing risk of developing preeclampsia. Therefore, the rising cases of preeclampsia across the globe are expected to boost the growth of the preeclampsia diagnostics market.

Increasing awareness among pregnant women is another key factor driving the growth of the preeclampsia diagnostics market. For example, in January 2025, in recognition of Maternal Health Awareness Day on January 23rd, the Preeclampsia Foundation, in collaboration with Patients & Purpose, launched the "GAP-SPIRIN" campaign. This evidence-based educational initiative promotes the use of low-dose aspirin to help prevent preeclampsia and address disparities in maternal health.

The campaign combines information on the unique challenges faced by Black expectant mothers with guidance on low-dose aspirin prophylaxis, equipping healthcare providers to better manage preeclampsia risk. Preeclampsia is a severe hypertensive condition that can pose life-threatening risks during pregnancy and the postpartum period. It is a central issue in the maternal health crisis, disproportionately affecting Black mothers, who are 60% more likely to develop the condition.

The development of innovative diagnostic tests by key market players is significantly contributing to market growth. A notable example is Mirvie, which in May 2022 announced it received U.S. FDA Breakthrough Device designation for its Mirvie Preeclampsia Test. This groundbreaking test is designed to assess a woman's individualized risk of developing preeclampsia before symptoms arise. It is powered by the proprietary Mirvie RNA platform, which analyzes the unique biological signals of each pregnancy to predict the risk of unexpected complications enabling earlier and more personalized clinical intervention.

Despite these promising growth factors, the preeclampsia diagnostics market faces challenges. Limited awareness among patients and providers and limitations in the accuracy of preeclampsia diagnostic tests are significant constraints that could potentially hinder market growth during the forecast period.

Preeclampsia Diagnostics Market Segment Analysis:

Preeclampsia Diagnostics Market by Sample Type (Blood Test and Urine Test), Product Type (Reagents & Kits, and Instruments), Mode of Testing (Laboratory-based Testing and Point-of-care Testing (POCT)), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the sample type segment of the preeclampsia diagnostics market, the blood test category held the largest revenue share in 2024. The growth of this category is attributed to the rising use of blood tests in preeclampsia diagnostics. These tests are playing a transformative role by enabling earlier, more accurate, and accessible detection of preeclampsia even before clinical symptoms manifest. Their ability to identify risk at an early stage allows for timely intervention, significantly improving maternal and fetal outcomes.

These tests provide precise risk stratification, helping clinicians predict which patients are more likely to develop severe preeclampsia. This capability supports the efficient use of hospital resources, minimizes unnecessary interventions, and enhances patient care. Moreover, blood-based diagnostics are highly scalable and easily integrated into routine prenatal care. As awareness of preeclampsia continues to grow, and as point-of-care testing becomes more accessible even in low-resource settings the demand for these tests is expected to increase.

A major advancement in this space is the development of biomarker-based blood tests, particularly those that measure levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1). These biomarkers allow healthcare providers to detect preeclampsia in its early or asymptomatic stages, offering a critical tool for proactive, personalized pregnancy management.

Recent innovations in molecular diagnostics and immunoassays have led to the development of advanced blood tests for preeclampsia. For instance, companies like Thermo Fisher Scientific, PerkinElmer, and Roche Diagnostics offer blood test-based platforms for preeclampsia detection. For instance, in May 2023, the U.S. FDA approved Thermo Scientific B*R*A*H*M*S PlGF plus KRYPTOR and B*R*A*H*M*S sFlt-1 KRYPTOR novel blood-based biomarker test for the risk assessment and clinical management of preeclampsia.

Thus, all these factors are fueling the adoption of blood tests, thereby acting as a strong catalyst in the growth of the blood-based preeclampsia test, thereby driving the overall expansion of the preeclampsia diagnostics market.

North America is expected to dominate the overall Preeclampsia Diagnostics Market:

North America is projected to account for the largest share of the preeclampsia diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising cases of preeclampsia, increased awareness among patients and healthcare providers, strong healthcare infrastructure, and widespread access to advanced diagnostic tools. Additionally, support from government initiatives and ongoing innovations by key players are further driving market expansion through the forecast period from 2025 to 2032.

According to the recent data provided by the Centre for Disease Control and Prevention (2022), preeclampsia is estimated to occur in 5 to 7 percent of all pregnancies in the US. Additionally, as per the same source, in the United States, the rate of preeclampsia in Black women is 60 percent higher than in White women.

Given the serious health risks it poses to both mother and baby, including preterm birth, placental abruption, and even maternal or fetal death, healthcare providers are placing increased emphasis on early screening and continuous monitoring thereby boosting the overall market of preeclampsia diagnostics across the region.

Moreover, growing product development activities among the key market players are likely to propel the revenue shares for the preeclampsia in the region. For example, In January 2024, Labcorp, a global leader in innovative and comprehensive laboratory services, announced the launch and availability of a new FDA-cleared blood test designed for the risk assessment and clinical management of severe preeclampsia, a potentially life-threatening blood pressure disorder that can occur during pregnancy and the postpartum period.

Preeclampsia Diagnostics Market Key Players:

Some of the key market players operating in the Preeclampsia Diagnostics Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Labcorp, PerkinElmer, ARUP Laboratories, Siemens Healthineers AG, QuidelOrtho Corporation, Revvity, Randox Laboratories, CERCA Biotech, and others.

Recent Developmental Activities in the Preeclampsia Diagnostics Market:

• In February 2025, Roche announced that its Elecsys(R) sFlt-1/PlGF ratio test for preeclampsia received 510(k) clearance from the U.S. FDA. The test was intended to stratify hospitalized pregnant women with hypertensive disorders into low- and high-risk groups for developing severe preeclampsia within two weeks. This enabled better prediction, earlier interventions, and reduced adverse outcomes.
• In May 2024, Labcorp launched its first-trimester preeclampsia screening test, designed to be performed between 11 and 14 weeks of gestation to assess the risk of developing preeclampsia before 34 weeks. It was the only test of its kind available in the U.S. and applied to all pregnant individuals, including those with low- to average-risk or first-time pregnancies.

Key Takeaways from the Preeclampsia Diagnostics Market Report Study

• Market size analysis for current preeclampsia diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the preeclampsia diagnostics market
• Various opportunities available for the other competitors in the preeclampsia diagnostics market space
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current preeclampsia diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for preeclampsia diagnostics market growth in the coming future?

Target Audience Who Can be benefited from this Preeclampsia Diagnostics Market Report Study

• Preeclampsia diagnostics product providers
• Research organizations and consulting companies
• Preeclampsia diagnostics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in preeclampsia diagnostics
• Various end-users who want to know more about the preeclampsia diagnostics market and the latest technological developments in the preeclampsia diagnostics market

Frequently Asked Questions for the Preeclampsia Diagnostics Market:

1. What are Preeclampsia Diagnostics?

• Preeclampsia diagnostics refers to the methods and tools used to detect preeclampsia, a pregnancy complication characterized by high blood pressure and signs of damage to other organs, often the liver and kidneys. Diagnostics typically involve blood pressure monitoring, urine protein tests, and biomarker-based blood tests (e.g., sFlt-1/PlGF ratio) to assess the risk, presence, or severity of the condition.

2. What is the market for Preeclampsia Diagnostics Market?

• The preeclampsia diagnostics market is estimated to grow at a CAGR of 3.67% during the forecast period from 2025 to 2032.

3. What are the drivers for the global Preeclampsia Diagnostics Market?

• The growth of the preeclampsia diagnostics market is primarily driven by the increasing incidence of preeclampsia and its associated risk factors, along with rising awareness among pregnant women and healthcare professionals. Additionally, ongoing product development initiatives by key market players are expected to further contribute to the market's expansion during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global Preeclampsia Diagnostics Market?

• Some of the key market players operating in the preeclampsia diagnostics market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Labcorp, PerkinElmer, ARUP Laboratories, Siemens Healthineers AG, QuidelOrtho Corporation, Revvity, Randox Laboratories, CERCA Biotech, and others.

5. Which region has the highest share in the global Preeclampsia Diagnostics Market?

• North America is expected to dominate the overall preeclampsia diagnostics market during the forecast period, 2025 to 2032. This dominance can be attributed to several key factors, including the rising cases of preeclampsia, increased awareness among patients and healthcare providers, strong healthcare infrastructure, and widespread access to advanced diagnostic tools. Additionally, support from government initiatives and ongoing innovations by key players are further driving market expansion through the forecast period from 2025 to 2032.

Table of Contents

1. Preeclampsia Diagnostics Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Preeclampsia Diagnostics Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Preeclampsia Diagnostics Market Key Factors Analysis

• 5.1. Preeclampsia Diagnostics Market Drivers
  • 5.1.1. Rising cases of preeclampsia and associated risk factors
  • 5.1.2. Rising awareness among pregnant women and healthcare professionals
  • 5.1.3. Growing product development activities among the key market players
• 5.2. Preeclampsia Diagnostics Market Restraints and Challenges
  • 5.2.1. Limited awareness among patients and providers
  • 5.2.2. Limitations in the accuracy of preeclampsia diagnostic tests
• 5.3. Preeclampsia Diagnostics Market Opportunities
  • 5.3.1. Ongoing research into novel biomarkers-based preeclampsia testing and home-based testing

6. Preeclampsia Diagnostics Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Preeclampsia Diagnostics Market Assessment

• 7.1. By Sample Type
  • 7.1.1. Blood Test
  • 7.1.2. Urine Test
• 7.2. By Product Type
  • 7.2.1. Reagents & Kits
  • 7.2.2. Instruments
• 7.3. Mode of Testing
  • 7.3.1. Laboratory-based Testing
  • 7.3.2. Point-of-care Testing (POCT)
• 7.4. By End-User
  • 7.4.1. Hospitals
  • 7.4.2. Specialty Clinics
  • 7.4.3. Diagnostic Centers
  • 7.4.4. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.1.2. Canada Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.1.3. Mexico Preeclampsia Diagnostics Market Size in USD million (2022-2032)
  • 7.5.2. Europe
    • 7.5.2.1. France Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.2.2. Germany Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.2.3. United Kingdom Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.2.4. Italy Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.2.5. Spain Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.2.6. Rest of Europe Preeclampsia Diagnostics Market Size in USD million (2022-2032)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.3.2. Japan Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.3.3. India Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.3.4. Australia Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.3.5. South Korea Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.3.6. Rest of Asia-Pacific Preeclampsia Diagnostics Market Size in USD million (2022-2032)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.4.2. Africa Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.4.3. South America Preeclampsia Diagnostics Market Size in USD million (2022-2032)

8. Preeclampsia Diagnostics Market Company and Product Profiles

• 8.1. F. Hoffmann-La Roche Ltd.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Thermo Fisher Scientific Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Labcorp
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. PerkinElmer
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. ARUP Laboratories
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Siemens Healthineers AG
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. QuidelOrtho Corporation
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Revvity
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Randox Laboratories
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. CERCA Biotech
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us